As news spreads of reports linking popular diabetes medications like Byetta with pancreatic cancer and thyroid cancer, more patients have filed a lawsuit against manufacturer Bristol-Myers Squibb for failing to disclose the dangers.
Now, a federal panel is set to conduct a hearing this week that will decide if the growing number of cases will be moved to one multidistrict litigation court rather than a Byetta class action lawsuit.
Byetta is one of the best-selling drugs for type-2 diabetes. The injectable medication allows those with the condition to produce more insulin, but may also limit the body’s natural ability to fight cancer.
After the FDA linked Byetta to pancreatitis, researchers at UCLA in 2011 discovered it may also be related to higher rates of pancreatic cancer and thyroid cancer. The American Medical Association has also warned that drugs like Byetta can double the risk factors for pancreatic cancer.
The FDA and American Diabetes Association have both asked that diabetes drugs like Byetta undergo new safety testing. However, the British Medical Journal recently reported that drug manufacturers have withheld data that could facilitate new testing.
Due to the widespread use of drugs like Byetta, experts fear that thousands may be affected. With Byetta cancer lawsuits already growing, the Judicial Panel on Multidistrict Litigation will hold a hearing on July 25th to decide where the cases will be consolidated in a special MDL court. This could be more of an advantage to victims than a class action lawsuit against Byetta.
If you or a loved one were diagnosed with cancer after taking Byetta, it is important to talk with a lawyer about your options. Because of the complexity of these cases, DrugRisk only recommends lawyers who have already handled Byetta lawsuits.
For more information on the research, side effects and litigation news related to Byetta, or to speak with a lawyer, contact us today.